section name header

Pronunciation ⬇

meth-a-ZOLE-a-mide

Classifications ⬆ ⬇

Therapeutic Classification: diuretics

Pharmacologic Classification: carbonic anhydrase inhibitors

Indications ⬆ ⬇

REMS


Action ⬆ ⬇

  • Inhibition of carbonic anhydrase in the eye results in decreased secretion of aqueous humor.
  • Inhibit renal carbonic anhydrase, resulting in self-limiting urinary excretion of sodium, potassium, bicarbonate, and water.
Therapeutic effects:
  • Lowering of intraocular pressure.

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed after oral administration.

Distribution: Crosses the placenta.

Metabolism/Excretion: 15–30% excreted unchanged in urine.

Half-Life: 14 hr.

Time/Action Profile ⬆ ⬇

(↓ intraocular pressure)
ROUTEONSETPEAKDURATION
PO2–4 hr6–8 hr10–18 hr

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Derm: rash

EENT: transient nearsightedness

Endo: hyperglycemia

F and E: hyperchloremic acidosis, hypokalemia

GI: anorexia, metallic taste, nausea, vomiting

GU: crystalluria, renal calculi

Hemat: APLASTIC ANEMIA, HEMOLYTIC ANEMIA, LEUKOPENIA

Metab: weight loss, hyperuricemia

Neuro: depression, fatigue, paresthesias, weakness, drowsiness

Misc: allergic reactions

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Neptazane

Code ⬆

NDC Code